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The occurrence of multi-drug resistant highly pathogenic avian influenza virus (HPAIV)
strains highlights the urgent need for strategies for the prevention and control of avian
influenza virus. The aim of our current study is to evaluate the antiviral activity of
dryocrassin ABBA isolated from Rhizoma Dryopteridis Crassirhizomatis (RDC) against
an amantadine-resistant H5N1 (A/Chicken/Hebei/706/2005) strain in a mouse model.
Post inoculation with HPAIV H5N1 virus in mice, the survival rate was 87, 80, and
60% respectively in the 33, 18, and 12.5 mg/kg dryocrassin ABBA-treated groups.
On the other hand, the survival rate was 53 and 20%, respectively in the amantadine-
treated group and untreated group. Mice administered with dryocrassin ABBA or
amantadine showed a significant weight increase compared to the untreated group.
Moreover, 33 and 18 mg/kg dryocrassin ABBA have decreased lung index (P > 0.05)
and virus loads (P < 0.01) compared to the untreated group on day 7. Also, on
day 7 bronchoalveolar lavage fluid pro-inflammatory cytokines (IL-6, TNF-α, and IFN-γ)
decreased significantly (P < 0.01) while anti-inflammatory cytokines (IL-10 and MCP-1)
were increased significantly (P < 0.01) in the 33 and 18 mg/kg dryocrassin ABBA-
treated groups compared to the amantadine group and the untreated group. Moreover,
the concentrations of IL-12 in drug-treated groups were significantly (P < 0.01) lowered
compared with the untreated group. Based on the above we conclude that orally
administered dryocrassin ABBA provided mice protection against avian influenza virus
H5N1 by inhibiting inflammation and reducing virus loads. Dryocrassin ABBA is a
potential novel lead compound which had antiviral effects on amantadine-resistant avian
influenza virus H5N1 infection.
Keywords: dryocrassin ABBA, influenza virus H5N1, phloroglucinol compound, antiviral activity, Rhizoma
Dryopteridis Crassirhizomatis, amantadine
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Introduction
Highly pathogenic avian inﬂuenza virus subtype H5N1 (HPAIV
H5N1) is responsible for large economic losses in the poultry
industry and poses a serious threat to public health (Kaye
and Pringle, 2005). The ﬁrst step in decreasing the risk of
human infection is to control the prevalence of HPAIV in
domestic poultry (Peiris et al., 2007). Enhanced bio-security
measures, such as surveillance, restriction of poultry movement
and eradication of infection foci are basic principles for the
control of HPAIV H5N1 epidemics in poultry, but these have
not prevented the spread of the virus since 1997 (Capua and
Alexander, 2006; Sarachai et al., 2014). Recently, several types
of avian inﬂuenza virus vaccines have been introduced in some
developing countries as a major control tool to reduce the
overwhelming socioeconomic impact of HPAI H5N1 outbreaks
in poultry (Swayne et al., 2011). Although vaccination is one of
the most eﬀective measures for preventing HPAIV, reports on
vaccine eﬃcacy in providing protection against HPAIV H5N1
outbreaks have not been encouraging (Suarez and Schultz-
Cherry, 2000; Suarez, 2005; Savill et al., 2006).
In developing countries, antiviral drugs for human use,
including amantadine hydrochloride and rimantadine, are widely
abused for the eradication of AIV in poultry (He et al., 2008;
Abdelwhab and Hafez, 2012). Accordingly, antiviral-resistant is
likely to be transmitted to human beings from poultry and
drug-resistant HPAIV H5N1 epidemics pose a major potential
public health threat. In this regard it is worth pointing out that
several H5N1 viruses from human and poultry were resistant
to amantadine (Cyranoski, 2005; He et al., 2008). Since the
late 1990s there has been an increase in recurrent amantadine-
resistant HPAIV H5N1 virus strains in poultry in China. This
has been attributed to extensive illegal application of the relatively
inexpensive amantadine and ribavirin against bird ﬂu in chickens
(Parry, 2005; Fan et al., 2015).
Rhizoma Dryopteris Crassirhizomae (RDC) has been
recorded in Atlas of Chinese traditional Medicine and is
rich in phloroglucinol compounds. Generally, RDC has been
traditionally used as a herbal medicine for treating various
inﬂammatory and infectious diseases such as tapeworm
infestation, colds, and viral diseases in humans. Recent
investigations demonstrated that phloroglucinol components
extracted from RDC had many pharmacological eﬀects, such
as anti-tumor promoting activity (Kapadia et al., 1996), anti-
reverse transcriptase activity (Nakane et al., 1991), antioxidant
activity (Lee et al., 2003), and antibacterial activity (Lee et al.,
2009). Furthermore, ﬂavaspidic acid AB derived from RDC
was able to signiﬁcantly induce IFN-α, IFN-β, and IL1-β
expression in porcine alveolar macrophages, suggesting that
induction of antiviral cytokines could contribute to inhibition of
porcine reproductive and respiratory syndrome virus (PRRSV)
replication (Yang et al., 2013a).
Recent evidences showed that RDC contained more than 10
components of phloroglucinol derivatives, such as dryocrassin
ABBA, ﬁlixic acid ABA, albaspidin AA, albaspidin AP, albaspidin
PP, ﬂavaspidic acid AB, and ﬂavaspidic acid PB (Lee et al., 2003),
and dryocrassin ABBA accounted for the highest proportion of
phloroglucinol components (Gao et al., 2008). In our pilot study,
a mixture of RDC and Fructus mumewas eﬀective in reducing the
death rate and viral replication in infectious bursal virus-infected
chickens (Ou et al., 2013). The aim of the current study is to
evaluate the protective eﬀects of dryocrassin ABBA on HPAIV
H5N1 infection in a mouse model.
Materials and Methods
Antiviral Drugs
Amantadine hydrochloride was purchased (Sigma-Aldrich,
Shanghai, China). Dryocrassin ABBA was isolated from RDC
and the purity was determined by high performance liquid
chromatography (HPLC). Phenomenex prodigy ODS column
(250 mm × 4.6 mm) was employed with a mobile phase of
acetonitrile: isopropanol: 0.3% phosphoric acid: 0.1% sodium
dodecyl sulfate (50:50:10:5). The sample was detected under
280 nmwavelength at 1.0mL/min. The ﬁnal purity wasmore than
99% of dryocrassin ABBA.
Virus
H5N1 Avian inﬂuenza A/Chicken/Hebei/706/2005
(108.7ELD50/0.1ml; H5N1) virus was isolated and identiﬁed
as previously described. The 50% inhibiting concentration
(IC50) of amantadine was determined to be 71.6 ± 3.5 μM (He
et al., 2008). The virus was donated by Prof. Jian Qiao, China
Agricultural University.
Animal Studies
SPF BALB/C female mice were purchased from Weitong Merial
Laboratory Animal Technology Co., Ltd (Beijing, China) and
maintained in a negative pressure isolator and provided food and
water ad libitum. Animal studies were approved by the Animal
Care and Use Committee of the China Agricultural University,
Beijing, China and conducted in bio-safety P3 lab. In the present
study, 120 female BALB/C mice were randomly divided into six
groups with 20 mice per group and all mice were maintained in
individually ventilated cages (IVC).
The control group was administrated saline intra-nasally
while the remaining ﬁve groups were inoculated intra-nasally
with 104.5ELD50 H5N1 viruses in 100 μl saline. On day 2
post inoculation mice received 0.2 ml of dryocrassin ABBA
or amantadine hydrochloride by oral gavages. The dosages
of the three dryocrassin ABBA groups were 12.5, 18.0, and
33 mg/kg body weight, and 20 mg/kg body weight of amantadine
hydrochloride was used as the positive drug control. Mice were
given drugs for 7 days from Day 2 to Day 8. Meanwhile,
the untreated and control groups received equivalent amounts
of physiological saline daily. Body weight, activity, mortality
rate, and survival time were monitored daily for 14 days post
inoculation.
Lung Index and Viral Load
Post inoculation on day 7 and on day 14, 5 mice were
euthanized to collect the lungs and the lung indexwas determined
as previously described: the dry lung-to-body weight ratio
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(%) = weight of the whole dry lung/body weight × 100% (Qiao
et al., 2009). Afterward, lung tissues were stored at −80◦C for
further virus quantitation. 50 mg tissue from each mouse was
minced to prepare the supernatant from lung homogenates.
Lung homogenates were then frozen at −80◦C and thawed
three times on ice. Homogenates were then centrifuged at
2000 rpm for 10 min at 4◦C. Supernatants were transferred
to sterile micro-centrifuge tubes and gentamicin added at the
concentration of 1000 U/ml for 30 min. Subsequently, 0.1 ml of
serial dilutions from 100 to 10−5 of the above preparations were
injected into the allantoic cavity of 10-days-old embryonated
SPF chicken eggs (Weitong Merial Laboratory Animal Co.,
Ltd., Beijing, China). Post inoculation from 12 to 96 h, any
dead or living embryos were collected to obtain allantoic ﬂuid.
A hemagglutination assay was used to determine the 50% egg
infective dose (EID50). Titers of infectious virus were presented
as log10 (EID50/0.1 ml).
Determination of Cytokines
The cytokine contents in bronchial alveolar lavage ﬂuid (BALF)
were used to assess the protective eﬃcacy of drug treatment
against AIV H5N1-derived pneumonia. Brieﬂy, three mice were
euthanized on day 7 post infection and the lungs were
lavaged twice with 1.0 ml sterile saline. Cell suspensions were
centrifuged at 1000 rpm for 5 min and the supernatants
were collected for cytokines determination. Then the BD CBA
Mouse Th1/Th2/Th17 Cytokine Kit (BD, USA) was used to
measure the titers of IL-12, IL-6, IL-10, INF-γ, MCP-1 and
TNF-α. Lung perfusion ﬂuids were added to tubes with the
mixed capture beads and then 50 μL PE of detection reagent
were added to all tubes. Samples were incubated, washed and
re-suspended for analysis using ﬂow cytometry (BD, USA).
Cytokine concentrations were calculated based on standard curve
data using FCAP Array software (BD, USA). The results are
expressed as mean ± SD. Comparisons between all groups
for each cytokine were performed by analysis of variances.
Diﬀerences between groups were considered signiﬁcant at
P < 0.05.
Statistical Analysis
Data were analyzed with the Statistical Package for Social Science
(SPSS, Version 13.0) for Windows and results were expressed as
means ± SD. Diﬀerent group of data were compared by Single
factor analysis of variance. Data were considered to be statistically
diﬀerent when P < 0.05 or signiﬁcantly diﬀerent when
P < 0.01.
Results
Structure and Purity Identification of
Dryocrassin ABBA
Dryocrassin ABBA (Figure 1A), the major phloroglucinol
component of RDC,was isolated by column chromatography and
re-crystallization and the structure was identiﬁed by spectroscopy
(data not shown). The purity of dryocrassin ABBA was analyzed
by HPLC and the ﬁnal purity was more than 99% (Figure 1B).
Therapeutic Efficacy of Dryocrassin ABBA
against HPAIV H5N1 Infection in Mice
Post inoculation with HPAIV H5N1, mice displayed typical signs
of infection, such as decreased activity, depression, and poor
food intake. On day 2, infected mice began to show weight
loss. Animals exhibited abdominal distention and shortness of
breath before death, usually on day 5. Dryocrassin ABBA and
amantadine signiﬁcantly reduced mortality, prolonged survival
rate, and improved survival time throughout the infection period,
compared with the untreated group. Obviously, dryocrassin
ABBA exerted a signiﬁcant dose-dependent antiviral eﬀect in
mice. The survival rates were 87, 80, and 60%, respectively
in the 33, 18, and 12.5 mg/kg dryocrassin ABBA groups. In
contrast, mice administered amantadine hydrochloride showed
53% survival while only 20%mice remained alive in the untreated
group (Figure 2A). Furthermore, a signiﬁcant increase in body
weight gain was observed in the dryocrassin ABBA-treated
groups compared to the amantadine-treated group and the
untreated group (Figure 2B).
The Effects of Dryocrassin ABBA on Lung
Index and Virus Loads
Post inoculation with H5N1 virus on day 7, mice infected
with inﬂuenza virus exhibited a signiﬁcantly greater lung
index compared to the control group (P < 0.01). However,
no signiﬁcant diﬀerence was found between the amantadine-
treated group and dryocrassin ABBA-treated groups. On day
14, the lung index decreased in virus-infected groups and no
statistical signiﬁcance was found among dryocrassin ABBA-
treated groups and the amantadine-treated group (Figure 3A).
The lung virus loads in both the 33 mg/kg group and 18 mg/kg
group were signiﬁcantly decreased compared to the untreated
group (P < 0.01) and were not signiﬁcantly diﬀerent from the
amantadine-treated group on day 7 (Figure 3B).
The Effects of Dryocrassin ABBA on BALF
Cytokine Levels
MCP-1 and IL-10 increased signiﬁcantly while IL-12, IL-6, IFN-γ
and TNF-α decreased signiﬁcantly in the 33 and 18 mg/kg
dryocrassin ABBA-treated groups compared to the amantadine-
treated group and the untreated group on day 7 (P < 0.01)
(Figure 4). The IL-6, IL-10 MCP-1 and IFN-γ displayed dose
dependent patterns.
Discussion
In the present study, mice administered with 33 mg/kg
of dryocrassin ABBA showed an 87% survival rate against
amantadine-resistant HPAIV H5N1. Moreover, body weight
gain increased signiﬁcantly while lung lesions and virus loads
were reduced compared to those of the untreated mice.
Moreover, the survival rates of dryocrassin ABBA-treated groups
were found to be a dose-dependent manner in the mouse
model. Thus dryocrassin ABBA might provide a promising
therapeutic approach against bird ﬂu virus in the poultry
industry. More importantly, dryocrassin ABBA could be used
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FIGURE 1 | Chemical structure and purity determination of dryocrassin ABBA. (A) Chemical structure of dryocrassin ABBA elucidated by related
spectroscopy. (B) The purity of dryocrassin ABBA was identified as more than 99% by HPLC and the retention time was 8.399 min.
as a potential novel lead compound which had antiviral
eﬀects on amantadine-resistant avian inﬂuenza virus H5N1
infection.
Generally, an ideal drug against bird ﬂu should have high
eﬃcacy, safety, good quality control, and availability. The threat
of a bird ﬂu-derived pandemic requires the development of new
therapeutic agents. Amantadine and its derivative rimantadine
have been shown to be therapeutically and prophylactically
eﬀective against human inﬂuenza A viruses (Zlydnikov et al.,
1981; Douglas, 1990). In Vietnam, Cambodia, and Thailand, the
emergence of amantadine-resistant H5N1 viruses has prompted
vaccine development (Cheung et al., 2006). An increasing
emergence of adamantine-resistant among seasonal inﬂuenza
viruses has been reported in isolates of both H1N1 and H3N2
subtypes (Bright et al., 2005, 2006; Dawood et al., 2009). It
is urgent to develop an eﬃcient and non-toxic antiviral agent
against the outbreak of bird ﬂu.
In the present study, dryocrassin ABBA has been shown to be
eﬀective against amantadine-resistant HPAIV H5N1, suggesting
a drug alternative against bird ﬂu-resistant strain. As for safety,
the maximum toxic dosage (MTD) of dryocrassin ABBA is up to
2000 mg/kg body weight in Sprague-Dawley rats (Hwang et al.,
2013) and it is considered a non-toxic substance according to
The European Pharmacopeia 7.0 version. From the standpoint
of quality control, both (Thin layer chromatography, TLC) and
HPLC can be employed to monitor the quality and control
the reliability post extraction from traditional Chinese medicine
(TCM). Furthermore, RDC grows widely in mountainous areas
in the Northeastern China and it is harvested from spring to
summer each year, assuring a rich supply of raw material for a
large scale manufacture.
Although mice administered dryocrassin ABBA in the present
study had a high survival rate and SPF chickens exhibited full
protection post inoculation with a virulent infectious bursal
disease virus (IBDV), the antiviral mechanism is unclear (Ou
et al., 2013). Following administration of dryocrassin ABBA,
the lung index of infected mice was signiﬁcantly reduced
compared to that of the amantadine and infection control groups,
suggesting the alleviation of lung lesions and inﬂammation.
In the previous report, HPAIV H5N1 virus was used to
induce acute respiratory distress symptoms, characterized with
by inﬂammatory cellular inﬁltration, interstitial and alveolar
edema, and hemorrhage (Xu et al., 2006). Our previous data
displayed that dryocrassin ABBA could not inhibit the inﬂuenza
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FIGURE 2 | Therapeutic efficacy of dryocrassin ABBA in mice infected
with influenza virus A/Chicken/Hebei/706/2005. (A) The mice survival
rate post administration with 33, 18, 12.5 mg/kg of dryocrassin ABBA or
20 mg/kg of amantadine hydrochloride. The infection control group was
inoculated with H5N1 virus without any medication. (B) The assessment of
mouse body weight post administration with dryocrassin ABBA or amantadine
hydrochloride as compared to the untreated or control animals on Day 7 and
14. ∗∗ Indicates a statistically significant differences (P < 0.01) in body weight
when the untreated group was compared with drug-treated groups on day 7
or 14.
virus replication in vivo (data not shown). The discrepancy
of anti-inﬂuenza activities for dryocrassin ABBA in vitro and
in vivo still needed to be explained. Reduced inﬂammation
would be expected to contribute to an increased survival
in infected animals. Dryocrassin ABBA administration might
contribute to virus clearance by modifying cytokine balance.
The pro-inﬂammatory cytokines, IL-6, TNF-α, IFN-γ, and IL-
12, were signiﬁcantly reduced while the anti-inﬂammation factors
(IL-10 and MCP-1) increased dramatically in mice administered
33 mg/kg dryocrassin ABBA. Furthermore, IL-10 is a key
immuno-regulator during infections, ameliorating the excessive
Th1 and CD8+ T cell responses responsible for much of
the immunopathology associated with HSV infections (Suvas
et al., 2004; Couper et al., 2008). The increased concentrations
of IL-10 and MCP-1 in dryocrassin ABBA-treated groups
showed a dose-dependent pattern. This dryocrassin ABBA
augmentation of MCP-1 and IL-10 might be responsible for
a reduced host injury during HPAIV infection. IL-10 is an
essential component of this regulatory response in almost
all infections. MCP-1 contributed to repair of the alveolar
epithelium in inﬂuenza pneumonitis (Dessing et al., 2007;
Narasaraju et al., 2010). In a recent report, an ethanol extract
of Dryopteris crassirhizoma displays strong anti-inﬂammatory
FIGURE 3 | The effects of dryocrassin ABBA on lung index (A) and
virus load (B) post inoculation with avian influenza virus
A/Chicken/Hebei/706/2005 (H5N1). (A) ∗∗ Indicates a statistically significant
differences (P < 0.01) in lung index between the control group and all other
virus-infected groups on Day 7 or14. (B) ∗∗ Indicates a statistically significant
differences (P < 0.01) in virus load when the untreated group was compared
with drug-treated groups on day 7; #Indicates a statistically significant
differences (P < 0.05) in virus load when the 12.5 mg/kg dryocrassin ABBA
group was compared with amantadine -treated group on day 7.
activity by suppressing ERK/AP-1 and TBK1/IRF3 pathways,
which contribute to its major ethno-pharmacological role as
an anti-inﬂammatory and anti-infectious disease remedy (Yang
et al., 2013b).
On other hand, the reduction in pro-inﬂammatory cytokines
(IL-6, IL-12, IFN-γ, and TNF-α) observed in the present
study, could have contributed to alleviation of lung lesions.
IL-6 and IL-12 have been reported to be key mediators of
acute lung injury in mice while IFN-γ and TNF-α were
associated with acute lung injury (Kishimoto, 2005; Imai et al.,
2008; Hagau et al., 2010). In the current study, the down-
regulation of IFN-γ and TNF-α was also dose-dependent in
mice administered with dryocrassin ABBA and these cytokines
might be involved with inﬂuenza virus replication in the lung.
IL-10 inhibits MHC class II and co-stimulatory molecule B7-
1/B7-2 expression on monocytes and macrophages, and limits
the production of pro-inﬂammatory cytokines (including IL-
1α and β, IL-6, IL-12, IL-18, and TNF-α) and chemokines
(MCP1, MCP5, RANTES, IL-8, IP-10, and MIP-2; Couper et al.,
2008).
Finally, dryocrassin ABBA might also be associated with
virus clearance by activation of signal transduction pathways.
Aspidin PB was capable of inducing apoptosis, as measured by
modulating the PI3K/Akt/GSK3b pathway (Sun et al., 2013).
Antiplatelet and anti-inﬂammatory eﬀects of phloroglucinol are
related to inhibition of COX, ROS, and TXA2 production as well
as ERK/p38 phosphorylation in platelets (Chang et al., 2012).
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FIGURE 4 | The effect of dryocrassin ABBA on the levels of the
inflammatory cytokines and anti-inflammatory cytokines (TNF-α,
IFN-γ, IL-12, IL-6, IL-10, and MCP-1) in BALF by flow cytometry
assay on day 7 post infection. (A) The concentration of MCP-1.
∗∗P < 0.01 when the untreated group was compared with dryocrassin
ABBA-treated groups or amantadine-treated group; ##P < 0.01 when the
amantadine group was compared with dryocrassin ABBA-treated groups.
(B) The concentration of IL-10. ∗∗P < 0.01 when the 33 and 18 mg/kg
dryocrassin ABBA-treated groups were compared with the untreated
group; ##P < 0.01 when the 33 and 18 mg/kg dryocrassin ABBA-treated
groups were compared with the amantadine group. (C) The concentration
of IL-12. ∗∗P < 0.01 when the untreated group was compared with the
amantadine- or dryocrassin ABBA-treated groups. (D) The concentration
of IL-6. ∗∗P < 0.01 when the untreated group was compared with the
amantadine- or dryocrassin ABBA-treated groups; ##P < 0.01 when the
33 and 18 mg/kg dryocrassin ABBA-treated groups were compared with
the amantadine group. (E) The concentration of IFN-γ. ∗∗P < 0.01 when
the untreated group was compared with the amantadine- or dryocrassin
ABBA-treated groups; ##P < 0.01 when the dryocrassin ABBA-treated
groups were compared with the amantadine group. (F) The concentration
of TNF-α. ∗∗P < 0.01 when the untreated group was compared with the
amantadine- or dryocrassin ABBA-treated groups; ##P < 0.01 when the
dryocrassin ABBA-treated groups were compared with the amantadine
group.
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Conclusion
In mice infected with an amantadine-resistant H5N1 strain,
dryocrassin ABBA provided a signiﬁcant improvement in
survival by alleviation of lung lesions and virus loads, eﬀects
was probably mediated by decreased pro-inﬂammatory cytokines
and increased anti-inﬂammatory cytokines. Dryocrassin
ABBA warrants further study as a promising therapeutic
agent against HPAIV H5N1. Future investigations will be
performed to understand the mechanisms and expand the
potential application of dyocrassin ABBA against other viral
diseases.
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